retatrutide

11/26/2022 - "We investigated the safety, pharmacokinetics, and pharmacodynamics of multiple weekly doses of LY3437943 in people with type 2 diabetes in a 12-week study. "
12/01/2023 - "We aimed to examine the efficacy and safety of retatrutide in people with type 2 diabetes across a range of doses. "
07/01/2023 - "Retatrutide showing promise in obesity (and type 2 diabetes)."
12/01/2023 - "In people with type 2 diabetes, retatrutide showed clinically meaningful improvements in glycaemic control and robust reductions in bodyweight, with a safety profile consistent with GLP-1 receptor agonists and GIP and GLP-1 receptor agonists. "
07/01/2023 - "Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM). "

07/01/2023 - "The results for retatrutide in phase 2 for obesity (and diabetes) are mostly encouraging. "
07/01/2023 - "Retatrutide showing promise in obesity (and type 2 diabetes)."
08/10/2023 - "In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. "
08/10/2023 - "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial."
10/26/2023 - "Triple-Hormone-Receptor Agonist Retatrutide for Obesity. "

08/10/2023 - "The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group. "
01/01/2022 - "In obese mice, administration of LY3437943 decreased body weight and improved glycemic control. "
08/10/2023 - "In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. "
01/01/2023 - "Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss."
05/01/2023 - "Although retatrutide may be superior to the GLP-1 receptor agonist dulaglutide in reducing plasma glucose and body weight, this is not a meaningful comparison, as another GLP-1 receptor agonist (semaglutide) is more potent than dulaglutide at this and may have similar efficacy to retatrutide. "

08/10/2023 - "At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. "
07/01/2023 - "Consistent with being a GLP-1 receptor agonist, heart rate was increased by up to 6.7 beats/min by retatrutide, which may be detrimental and offset some of the benefits of weight loss. "
07/01/2023 - "Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM). "
07/01/2023 - "Although the reductions in HbA1c and dose-dependent weight loss among individuals with T2DM were significantly more for higher doses of retatrutide, it needs to be observed that the active comparator was dulaglutide, which is not approved for the treatment of obesity, at a dose of 1.5 mg, which is much lower than the highest approved dose of 4.5 mg. "
07/01/2023 - "Presumably, retatrutide is being developed as a challenger to the recently developed weight loss medicines; semaglutide and/or tirzepatide. "

01/01/2023 - "EECs are hormone-producing cells expressed throughout the gastrointestinal epithelium and have been leveraged by pharmaceuticals like semaglutide (Ozempic, Wegovy), terzepatide (Mounjaro), and retatrutide (Phase 2) for diabetes and weight control, and linaclotide (Linzess) to treat irritable bowel syndrome (IBS) and visceral pain. "